Hilleman Business Plan FY2025-FY2030

Since April 2021, Hilleman expanded its vaccine portfolio from cholera and meningitis to viral, recombinant and mRNA vaccines. We invested in four vaccine platforms and raised $39.1M in external funding to support our infrastructure and operations. From 2025-2027, we will oversee the implementation of Hillchol™in India and GAVI countries, complete the development and licensure of Ervebo® second generation with our collaborators, advance MenACWYX, CircRNA-Nipah, Lassa and Q-Fever vaccines to Phase I through external funding and partnerships, and manufacture 5 GMP batches at ACES. We will secure $10M from Singapore EDB to support ACES operations, $21M for Disease X vaccines and secure funding through grants (UKRI, CEPI, BMGF) and out licensing revenues from commercial partnerships. From April 2027, we expect to receive $3M/year from EDB to support ACES operations and extend EDB grant support for 43 FTEs beyond 2026, develop Hillchol-rCTB, oversee the licensure of Lassa, MenACWYX, advance vaccines against sevaral endemic diseases to Phase II, and manufacture forty 44 GMP batches. The implementation of Hillchol™, Ervebo®, Lassa, Nipah and MenACWYX vaccines could impact disease burden for 150M people in LMICs with a potential for 500M more with vaccines against other endemic diseases.